Brian Patrick Brennan, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Obsessive-Compulsive Disorder | 19 | 2024 | 1491 | 2.640 |
Why?
|
Glutamic Acid | 4 | 2017 | 1175 | 0.960 |
Why?
|
Glutamine | 3 | 2017 | 576 | 0.880 |
Why?
|
Gyrus Cinguli | 4 | 2017 | 1115 | 0.760 |
Why?
|
Residential Treatment | 4 | 2018 | 111 | 0.640 |
Why?
|
Citalopram | 1 | 2017 | 402 | 0.470 |
Why?
|
Antidepressive Agents | 5 | 2017 | 2896 | 0.460 |
Why?
|
Acetylcarnitine | 1 | 2013 | 9 | 0.450 |
Why?
|
Thioctic Acid | 1 | 2013 | 28 | 0.450 |
Why?
|
Behavior Therapy | 1 | 2018 | 877 | 0.420 |
Why?
|
Performance-Enhancing Substances | 1 | 2013 | 30 | 0.410 |
Why?
|
Anabolic Agents | 2 | 2015 | 256 | 0.400 |
Why?
|
Magnetic Resonance Spectroscopy | 4 | 2017 | 3769 | 0.380 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2017 | 1140 | 0.370 |
Why?
|
Psychiatric Status Rating Scales | 7 | 2018 | 6016 | 0.370 |
Why?
|
Doping in Sports | 1 | 2010 | 62 | 0.350 |
Why?
|
Self Medication | 1 | 2010 | 117 | 0.350 |
Why?
|
Riluzole | 1 | 2009 | 59 | 0.340 |
Why?
|
Bipolar Disorder | 4 | 2021 | 5091 | 0.320 |
Why?
|
Memantine | 1 | 2008 | 108 | 0.290 |
Why?
|
Dopamine Agents | 1 | 2008 | 189 | 0.290 |
Why?
|
Androgens | 2 | 2015 | 1285 | 0.290 |
Why?
|
Cerebral Cortex | 3 | 2021 | 5776 | 0.270 |
Why?
|
Implosive Therapy | 2 | 2018 | 125 | 0.270 |
Why?
|
Bulimia Nervosa | 1 | 2008 | 206 | 0.270 |
Why?
|
Human Growth Hormone | 1 | 2010 | 642 | 0.250 |
Why?
|
Depressive Disorder, Major | 3 | 2021 | 4764 | 0.250 |
Why?
|
Thiophenes | 1 | 2009 | 569 | 0.240 |
Why?
|
Mental Disorders | 2 | 2022 | 6826 | 0.240 |
Why?
|
Irritable Bowel Syndrome | 1 | 2009 | 452 | 0.220 |
Why?
|
Synaptic Transmission | 1 | 2009 | 1169 | 0.220 |
Why?
|
Athletes | 1 | 2010 | 1137 | 0.210 |
Why?
|
Human Development | 2 | 2021 | 123 | 0.210 |
Why?
|
Analgesics | 1 | 2009 | 1066 | 0.200 |
Why?
|
Internet | 1 | 2013 | 3090 | 0.180 |
Why?
|
Public Health | 1 | 2013 | 2669 | 0.170 |
Why?
|
Brain | 9 | 2024 | 27101 | 0.170 |
Why?
|
Cerebrum | 1 | 2020 | 132 | 0.160 |
Why?
|
Young Adult | 12 | 2024 | 59179 | 0.150 |
Why?
|
Adult | 23 | 2024 | 220969 | 0.140 |
Why?
|
Extinction, Psychological | 1 | 2018 | 371 | 0.120 |
Why?
|
Fetal Development | 1 | 2021 | 769 | 0.120 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2021 | 3708 | 0.120 |
Why?
|
Thinking | 1 | 2018 | 319 | 0.120 |
Why?
|
Adolescent | 11 | 2024 | 88234 | 0.110 |
Why?
|
Substance-Related Disorders | 1 | 2010 | 4416 | 0.110 |
Why?
|
Neurosciences | 1 | 2018 | 367 | 0.110 |
Why?
|
Linear Models | 2 | 2014 | 5866 | 0.110 |
Why?
|
Sarcoma, Synovial | 1 | 2014 | 153 | 0.110 |
Why?
|
Diffusion Tensor Imaging | 1 | 2024 | 2400 | 0.110 |
Why?
|
Humans | 33 | 2024 | 760617 | 0.110 |
Why?
|
Phosphocreatine | 1 | 2013 | 261 | 0.100 |
Why?
|
Neural Pathways | 3 | 2019 | 3056 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 36402 | 0.100 |
Why?
|
Male | 21 | 2024 | 360358 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 3 | 2019 | 8998 | 0.100 |
Why?
|
Middle Aged | 13 | 2024 | 220584 | 0.100 |
Why?
|
Disability Evaluation | 2 | 2009 | 1835 | 0.100 |
Why?
|
Female | 18 | 2024 | 392148 | 0.090 |
Why?
|
Severity of Illness Index | 3 | 2018 | 15828 | 0.090 |
Why?
|
Consumer Health Information | 1 | 2013 | 215 | 0.090 |
Why?
|
Deep Brain Stimulation | 1 | 2018 | 831 | 0.090 |
Why?
|
Resilience, Psychological | 1 | 2017 | 786 | 0.080 |
Why?
|
Fear | 1 | 2018 | 1477 | 0.080 |
Why?
|
Mitochondria | 2 | 2013 | 3619 | 0.080 |
Why?
|
Testosterone | 2 | 2011 | 2472 | 0.080 |
Why?
|
Protons | 1 | 2015 | 1112 | 0.080 |
Why?
|
Antipsychotic Agents | 1 | 2022 | 3066 | 0.080 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2018 | 1473 | 0.080 |
Why?
|
Time Factors | 4 | 2018 | 39913 | 0.080 |
Why?
|
Psychometrics | 1 | 2018 | 3060 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2018 | 64568 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7568 | 0.070 |
Why?
|
Motivation | 1 | 2017 | 2003 | 0.070 |
Why?
|
Erectile Dysfunction | 1 | 2011 | 444 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3410 | 0.070 |
Why?
|
Brain Mapping | 2 | 2019 | 6634 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2013 | 6305 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1158 | 0.060 |
Why?
|
Neuropsychological Tests | 2 | 2015 | 7050 | 0.060 |
Why?
|
Oxygen | 1 | 2015 | 4226 | 0.050 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2008 | 894 | 0.050 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2010 | 1932 | 0.050 |
Why?
|
Energy Metabolism | 1 | 2013 | 2878 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2017 | 4488 | 0.050 |
Why?
|
Schizophrenia | 1 | 2021 | 6929 | 0.050 |
Why?
|
Compulsive Personality Disorder | 1 | 2021 | 48 | 0.050 |
Why?
|
Alcohol Drinking | 1 | 2014 | 4025 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2017 | 14591 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2015 | 3979 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2011 | 2187 | 0.050 |
Why?
|
Child | 7 | 2024 | 80079 | 0.040 |
Why?
|
Knowledge | 1 | 2021 | 177 | 0.040 |
Why?
|
Systems Analysis | 1 | 2020 | 169 | 0.040 |
Why?
|
Pain Measurement | 1 | 2009 | 3546 | 0.040 |
Why?
|
Quality of Life | 4 | 2018 | 13347 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2021 | 943 | 0.040 |
Why?
|
Psychopathology | 1 | 2020 | 432 | 0.040 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.030 |
Why?
|
Benzodiazepines | 1 | 2022 | 1132 | 0.030 |
Why?
|
Frontal Lobe | 1 | 2022 | 1418 | 0.030 |
Why?
|
Pilot Projects | 1 | 2009 | 8618 | 0.030 |
Why?
|
Aged | 5 | 2022 | 169042 | 0.030 |
Why?
|
Canada | 1 | 2021 | 2118 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 997 | 0.030 |
Why?
|
Organ Size | 1 | 2020 | 2252 | 0.030 |
Why?
|
Child, Preschool | 3 | 2022 | 42188 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2020 | 1700 | 0.030 |
Why?
|
Longevity | 1 | 2022 | 1064 | 0.030 |
Why?
|
Models, Psychological | 1 | 2018 | 829 | 0.030 |
Why?
|
Inositol | 1 | 2015 | 215 | 0.030 |
Why?
|
Hypertrophy | 1 | 2015 | 560 | 0.030 |
Why?
|
Thalamus | 1 | 2019 | 1047 | 0.030 |
Why?
|
Genes, Mitochondrial | 1 | 2012 | 58 | 0.030 |
Why?
|
Prefrontal Cortex | 1 | 2022 | 2219 | 0.020 |
Why?
|
Free Radical Scavengers | 1 | 2012 | 211 | 0.020 |
Why?
|
Nootropic Agents | 1 | 2012 | 157 | 0.020 |
Why?
|
Depression | 1 | 2011 | 8132 | 0.020 |
Why?
|
Body Mass Index | 1 | 2008 | 12943 | 0.020 |
Why?
|
Comorbidity | 2 | 2018 | 10505 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2021 | 22148 | 0.020 |
Why?
|
Oxidative Phosphorylation | 1 | 2012 | 495 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2018 | 20074 | 0.020 |
Why?
|
Gels | 1 | 2010 | 420 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3509 | 0.020 |
Why?
|
Prospective Studies | 2 | 2014 | 54360 | 0.020 |
Why?
|
Israel | 1 | 2011 | 716 | 0.020 |
Why?
|
Glycolysis | 1 | 2012 | 835 | 0.020 |
Why?
|
Europe | 1 | 2014 | 3413 | 0.020 |
Why?
|
Amygdala | 1 | 2015 | 1353 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2010 | 1575 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2011 | 12334 | 0.020 |
Why?
|
Obesity | 1 | 2008 | 12933 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8833 | 0.020 |
Why?
|
Neuroprotective Agents | 1 | 2012 | 957 | 0.020 |
Why?
|
Hormone Replacement Therapy | 1 | 2011 | 750 | 0.020 |
Why?
|
Down-Regulation | 1 | 2012 | 2915 | 0.020 |
Why?
|
Up-Regulation | 1 | 2012 | 4117 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26049 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2012 | 3113 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2011 | 10754 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 14018 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41457 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 58894 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2014 | 39063 | 0.010 |
Why?
|
Animals | 1 | 2018 | 168201 | 0.000 |
Why?
|
United States | 1 | 2011 | 72272 | 0.000 |
Why?
|